FinanceCity
HealthcareNSE · BSE

Syngene International Limited

SYNGENE · ISIN INE398R01022

Share price

₹452 -0.35%

Market capitalisation

₹18160 CrClosed

Live from Yahoo Finance. Pulse animates during NSE market hours (9:15–15:30 IST, weekdays).

01 · Key metrics

Market cap

₹18160 Cr

Current price

₹452

-0.35% today

52W high

₹729

52W low

₹380

Stock P/E

57.28

P/B ratio

3.75

02 · Per share & returns

EPS (TTM)

₹7.89

Book value

₹120

ROE

6.62%

ROA

4.75%

Dividend yield

0.28%

Beta

-0

03 · Financials (TTM)

By the numbers

Revenue

₹3739 Cr

+1.80% YoY

EBITDA

₹979 Cr

Net profit

₹317 Cr

-19.50% YoY

Profit margin

8.47%

Operating margin

20.55%

Total debt

₹458 Cr

Total cash

₹1289 Cr

Debt / equity

0.09x

Current ratio

1.38x

Payout ratio

15.88%

04 · Analyst view

Target price

₹578

Upside

+27.93%

Consensus

BUY

Analysts

8

05 · Shareholding pattern

Who owns SYNGENE?

  • Promoters

    52.68%

    Founders & promoter group

  • Institutions

    38.41%

    FII + DII

  • Public

    8.91%

    Retail & non-institutional

As of 31 Mar 2026 · Source: NSE corporate filings

06 · Registration & listing

On the record

Symbol
SYNGENE
Exchange
NSE · BSE
CIN
ISIN
INE398R01022
BSE code
539268
Sector
Healthcare
Industry
Healthcare
Face value
₹10
Listing date
10 Aug 2015
Employees
Headquarters
Bengaluru, India

07 · About

What is Syngene International Limited?

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

08 · Common questions

Frequently asked

What is the CIN of Syngene International Limited?+

The Corporate Identity Number for Syngene International Limited is published in the MCA21 corporate master. FinanceCity backfills CIN values during weekly refreshes.

Who are the promoters of Syngene International Limited?+

Promoter holding in SYNGENE is approximately 52.68%, as disclosed in the latest published shareholding pattern.

What is the market capitalisation of Syngene International Limited?+

Syngene International Limited (SYNGENE) has a market capitalisation of approximately ₹18160 Cr, reflecting the most recent weekly refresh from the BSE scrip master.

09 · Adjacent

Other healthcare listings

Full sector →